{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:31:36Z","timestamp":1781620296281,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-34772-z","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:45:07Z","timestamp":1769229907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic significance of POD24 in primary central nervous system diffuse large B-cell lymphoma: a retrospective study"],"prefix":"10.1038","volume":"16","author":[{"given":"Yuye","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"34772_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-022-01356-7","volume":"15","author":"T Chen","year":"2022","unstructured":"Chen, T. et al. Evidence-based expert consensus on the management of primary central nervous system lymphoma in China. J. Hematol. Oncol. 15, 136 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"34772_CR2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","volume":"21","author":"AJ Ferreri","year":"2003","unstructured":"Ferreri, A. J. et al. Prognostic scoring system for primary CNS lymphomas: The international extranodal lymphoma study group experience. J. Clin. Oncol. 21, 266\u2013272 (2003).","journal-title":"J. Clin. Oncol."},{"key":"34772_CR3","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","volume":"24","author":"LE Abrey","year":"2006","unstructured":"Abrey, L. E. et al. Primary central nervous system lymphoma: The memorial Sloan-Kettering cancer center prognostic model. J. Clin. Oncol. 24, 5711\u20135715 (2006).","journal-title":"J. Clin. Oncol."},{"key":"34772_CR4","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/cam4.2872","volume":"9","author":"CJ Liu","year":"2020","unstructured":"Liu, C. J. et al. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma. Cancer Med. 9, 2134\u20132145 (2020).","journal-title":"Cancer Med."},{"key":"34772_CR5","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo, C. et al. Early relapse of follicular lymphoma after rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and prednisone defines patients at high risk for death: An analysis from the National lymphocare study. J. Clin. Oncol. 33, 2516\u20132522 (2015).","journal-title":"J. Clin. Oncol."},{"key":"34772_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-023-01448-y","volume":"16","author":"N Epperla","year":"2023","unstructured":"Epperla, N. et al. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study. J. Hematol. Oncol. 16, 49 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"34772_CR7","doi-asserted-by":"publisher","first-page":"2304483","DOI":"10.1080\/16078454.2024.2304483","volume":"29","author":"H Chen","year":"2024","unstructured":"Chen, H. et al. The prognostic significance of POD24 in peripheral T-cell lymphoma. Hematology 29, 2304483 (2024).","journal-title":"Hematology"},{"key":"34772_CR8","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer, M. J. et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J. Clin. Oncol. 32, 1066\u20131073 (2014).","journal-title":"J. Clin. Oncol."},{"key":"34772_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41409-022-01605-w","volume":"57","author":"SE Yoon","year":"2022","unstructured":"Yoon, S. E. et al. Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: Real-world data from a retrospective single-center analysis. Bone Marrow Transpl. 57, 641\u2013648 (2022).","journal-title":"Bone Marrow Transpl."},{"key":"34772_CR10","doi-asserted-by":"publisher","first-page":"817043","DOI":"10.3389\/fonc.2022.817043","volume":"12","author":"D Tang","year":"2022","unstructured":"Tang, D. et al. Epidemiologic characteristics, prognostic Factors, and treatment outcomes in primary central nervous system lymphoma: A SEER-Based study. Front. Oncol. 12, 817043 (2022).","journal-title":"Front. Oncol."},{"key":"34772_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","volume":"107","author":"S Camilleri-Bro\u00ebt","year":"2006","unstructured":"Camilleri-Bro\u00ebt, S. et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: Analysis of 83 cases. Blood 107, 190\u2013196 (2006).","journal-title":"Blood"},{"key":"34772_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/PAI.0000000000000424","volume":"26","author":"U Cho","year":"2018","unstructured":"Cho, U., Oh, W. J., Hong, Y. K. & Lee, Y. S. Prognostic significance of high Ki-67 index and histogenetic subclassification in primary central nervous system lymphoma. Appl. Immunohistochem. Mol. Morphol. 26, 254\u2013262 (2018).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"34772_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/1120009X.2018.1546984","volume":"31","author":"H Kobayashi","year":"2019","unstructured":"Kobayashi, H. et al. Long-Term evaluation of combination treatment of single agent HD-MTX chemotherapy up to three cycles and moderate dose whole brain irradiation for primary CNS lymphoma. J. Chemother. 31, 35\u201341 (2019).","journal-title":"J. Chemother."},{"key":"34772_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/nox187","volume":"20","author":"JS Mendez","year":"2018","unstructured":"Mendez, J. S. et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 20, 687\u2013694 (2018).","journal-title":"Neuro Oncol."},{"key":"34772_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjh.17747","volume":"195","author":"FA Kaji","year":"2021","unstructured":"Kaji, F. A. et al. Improved survival outcomes despite older age at diagnosis: An era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the united Kingdom. Br. J. Haematol. 195, 561\u2013570 (2021).","journal-title":"Br. J. Haematol."},{"key":"34772_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","volume":"80","author":"K Jahnke","year":"2006","unstructured":"Jahnke, K. et al. Relapse of primary central nervous system lymphoma: Clinical features, outcome and prognostic factors. J. Neurooncol. 80, 159\u2013165 (2006).","journal-title":"J. Neurooncol"},{"key":"34772_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1200\/EDBK_200829","volume":"38","author":"JS Mendez","year":"2018","unstructured":"Mendez, J. S. & Grommes, C. Treatment of primary central nervous system lymphoma: From chemotherapy to small molecules. Am. Soc. Clin. Oncol. Educ. Book. 38, 604\u2013615 (2018).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"34772_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3892\/ijo.2021.5180","volume":"58","author":"Y Liu","year":"2021","unstructured":"Liu, Y., Yao, Q. & Zhang, F. Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review). Int. J. Oncol. 58, 371\u2013387 (2021).","journal-title":"Int. J. Oncol."},{"key":"34772_CR19","first-page":"9937","volume":"8","author":"Y Meng","year":"2015","unstructured":"Meng, Y. et al. High prevalence of hepatitis B virus infection in primary central nervous system lymphoma. Int. J. Clin. Exp. Med. 8, 9937\u20139942 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"34772_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13027-021-00396-x","volume":"16","author":"DG Chen","year":"2021","unstructured":"Chen, D. G. et al. Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: A single-center retrospective study in China. Infect. Agent Cancer. 16, 57 (2021).","journal-title":"Infect. Agent Cancer"},{"key":"34772_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12883-021-02227-3","volume":"21","author":"S Wu","year":"2021","unstructured":"Wu, S. et al. The role of surgical resection in primary central nervous system lymphoma: A single-center retrospective analysis of 70 patients. BMC Neurol. 21, 190 (2021).","journal-title":"BMC Neurol."},{"key":"34772_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.5603\/RPOR.a2023.0028","volume":"28","author":"A Thomas","year":"2023","unstructured":"Thomas, A. et al. Radiotherapy for newly diagnosed primary central nervous system lymphoma: Role and perspective. Rep. Pract. Oncol. Radiother. 28, 271\u2013285 (2023).","journal-title":"Rep. Pract. Oncol. Radiother"},{"key":"34772_CR23","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3171\/2020.9.JNS201980","volume":"135","author":"N Schellekes","year":"2021","unstructured":"Schellekes, N. et al. Resection of primary central nervous system lymphoma: Impact of patient selection on overall survival. J. Neurosurg. 135, 1016\u20131025 (2021).","journal-title":"J. Neurosurg."},{"key":"34772_CR24","doi-asserted-by":"publisher","first-page":"e1436","DOI":"10.1016\/j.wneu.2019.02.252","volume":"126","author":"CM Labak","year":"2019","unstructured":"Labak, C. M. et al. Surgical resection for primary central nervous system lymphoma: A systematic review. World Neurosurg. 126, e1436\u2013e1448 (2019).","journal-title":"World Neurosurg."},{"key":"34772_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11060-016-2358-8","volume":"132","author":"MB Cloney","year":"2017","unstructured":"Cloney, M. B. et al. The safety of resection for primary central nervous system lymphoma: A single institution retrospective analysis. J. Neurooncol. 132, 189\u2013197 (2017).","journal-title":"J. Neurooncol"},{"key":"34772_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3389\/fneur.2017.00478","volume":"8","author":"J Yun","year":"2017","unstructured":"Yun, J. et al. Assessing the safety of craniotomy for resection of primary central nervous system lymphoma: A nationwide inpatient sample analysis. Front. Neurol. 8, 478 (2017).","journal-title":"Front. Neurol."},{"key":"34772_CR27","doi-asserted-by":"crossref","unstructured":"Van Dijck, R., Doorduijn, J. K. & Bromberg, J. The role of rituximab in the treatment of primary central nervous system lymphoma. Cancers (Basel) 13, (2021).","DOI":"10.3390\/cancers13081920"},{"key":"34772_CR28","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/neuonc\/noad224","volume":"26","author":"J Bromberg","year":"2024","unstructured":"Bromberg, J. et al. Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105\/ALLG NHL 24 study. Neuro Oncol. 26, 724\u2013734 (2024).","journal-title":"Neuro Oncol."},{"key":"34772_CR29","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.22.00491","volume":"40","author":"C Houillier","year":"2022","unstructured":"Houillier, C. et al. Radiotherapy or autologous Stem-Cell transplantation for primary CNS lymphoma in patients age 60 years and younger: Long-Term results of the randomized phase II PRECIS study. J. Clin. Oncol. 40, 3692\u20133698 (2022).","journal-title":"J. Clin. Oncol."},{"key":"34772_CR30","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"A Ferreri","year":"2017","unstructured":"Ferreri, A. et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: Results of the second randomisation of the international extranodal lymphoma study Group-32 phase 2 trial. Lancet Haematol. 4, e510\u2013e523 (2017).","journal-title":"Lancet Haematol."},{"key":"34772_CR31","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier, C. et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: Results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J. Clin. Oncol. 37, 823\u2013833 (2019).","journal-title":"J. Clin. Oncol."},{"key":"34772_CR32","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/bloodadvances.2024014073","volume":"9","author":"SR Hwang","year":"2025","unstructured":"Hwang, S. R. et al. Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: A Mayo clinic experience. Blood Adv. 9, 924\u2013932 (2025).","journal-title":"Blood Adv."},{"key":"34772_CR33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00277-023-05092-x","volume":"102","author":"F Wang","year":"2023","unstructured":"Wang, F. et al. Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab. Ann. Hematol. 102, 393\u2013402 (2023).","journal-title":"Ann. Hematol."},{"key":"34772_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11060-021-03708-8","volume":"152","author":"M van der Meulen","year":"2021","unstructured":"van der Meulen, M. et al. MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma. J. Neurooncol. 152, 357\u2013362 (2021).","journal-title":"J. Neurooncol"},{"key":"34772_CR35","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00277-017-3068-9","volume":"96","author":"JC Jo","year":"2017","unstructured":"Jo, J. C. et al. Interim (18)F-FGD PET\/CT May not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine. Ann. Hematol. 96, 1509\u20131515 (2017).","journal-title":"Ann. Hematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34772-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34772-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34772-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T10:43:28Z","timestamp":1770633808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34772-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34772"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34772-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7100334\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5443"}}